Last reviewed · How we verify

NCT05361993

Efficacy of Biofeedback in the Treatment of Tic Disorder

Withdrawn Phase 4 Last updated 20 January 2025
What this trial tests

Phase 4 trial testing Drug Aripiprazole in Tic Disorders. Withdrawn.

Timeline
1 June 2024
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorChildren's Hospital of Fudan University
PhasePhase 4
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Start date1 June 2024
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Children's Hospital of Fudan University

Who can join

Adults 8 to 16, any sex, with Tic Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the efficacy of EEG biofeedback and drug therapy in the treatment of tic disorders

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Tic Disorders

Currently open trials in the same condition.

Other Children's Hospital of Fudan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05361993.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing